Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mayhew GM"'
Autor:
Eisner JR; GeneCentric Therapeutics, Inc., Durham, NC, United States., de Jong FC; Erasmus MC, Rotterdam, South Holland, Netherlands., Shibata Y; Genecentric, Durham, NC, United States., Mayhew GM; Genecentric, Durham, NC, United States., Davison JM; GeneCentric Therapeutics, Inc., Durham, NC, United States., Carcione J; Janssen Research & Development, LLC, United States., Pappan KL; GeneCentric Therapeutics, Durham, United States., Thomas S; Virginia Commonwealth University, Richmond, VA, United States., Triantos S; Janssen (United States), Spring House, PA, United States., Santiago-Walker A; Johnson & Johnson (United States), Spring House, PA, United States., Baig M; Janssen Research & Development, LLC, Raritan, United States., Milburn MV; Genecentric, United States., Beebe KD; GeneCentric Therapeutics, Inc., Durham, NC, United States., Zuiverloon TCM; Erasmus MC Cancer Institute, Rotterdam, Zuid-Holland, Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 26. Date of Electronic Publication: 2024 Sep 26.
Autor:
Eisner JR; GeneCentric Therapeutics, Inc., Durham, North Carolina., Mayhew GM; GeneCentric Therapeutics, Inc., Durham, North Carolina., Davison JM; GeneCentric Therapeutics, Inc., Durham, North Carolina., Beebe KD; GeneCentric Therapeutics, Inc., Durham, North Carolina., Shibata Y; GeneCentric Therapeutics, Inc., Durham, North Carolina., Guo Y; GeneCentric Therapeutics, Inc., Durham, North Carolina., Farhangfar C; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Farhangfar F; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Uronis JM; GeneCentric Therapeutics, Inc., Durham, North Carolina., Conroy JM; OmniSeq, A Subsidiary of Labcorp, Buffalo, New York., Milburn MV; GeneCentric Therapeutics, Inc., Durham, North Carolina., Hayes DN; University of Tennessee Health Science Center, Center for Cancer Research, Memphis, Tennessee., Mileham KF; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Aug 15; Vol. 29 (16), pp. 3203-3213.
Autor:
Mayhew GM; Department of Bioinformatics and Biostatstics, GeneCentric Therapeutics Inc., Durham, NC, United States., Uronis JM; Department of Genomics Sequencing Operations, GeneCentric Therapeutics Inc., Durham, NC, United States., Hayes DN; Department of Medical Oncology, University of Tennessee Health Sciences West Cancer Center, Memphis, TN, United States., Zevallos JP; Department of Otolaryngology-Head and Neck Surgery , Washington University School of Medicine in St. Louis, MO, United States.
Publikováno v:
Frontiers in oncology [Front Oncol] 2022 Sep 06; Vol. 12, pp. 954037. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022).
Autor:
Eisner JR; GeneCentric Therapeutics, Inc., Durham, North Carolina., Beebe KD; GeneCentric Therapeutics, Inc., Durham, North Carolina., Mayhew GM; GeneCentric Therapeutics, Inc., Durham, North Carolina., Shibata Y; GeneCentric Therapeutics, Inc., Durham, North Carolina., Guo Y; GeneCentric Therapeutics, Inc., Durham, North Carolina., Farhangfar C; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Farhangfar F; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Uronis JM; GeneCentric Therapeutics, Inc., Durham, North Carolina., Mooney J; Synthorx, Inc - A Sanofi Company, La Jolla, California., Milburn MV; GeneCentric Therapeutics, Inc., Durham, North Carolina., Foureau D; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., White RL; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Amin A; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Milla ME; Synthorx, Inc - A Sanofi Company, La Jolla, California.
Publikováno v:
Cancer research communications [Cancer Res Commun] 2022 Aug 30; Vol. 2 (8), pp. 894-903. Date of Electronic Publication: 2022 Aug 30 (Print Publication: 2022).
Autor:
Rose TL; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Weir WH; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Mayhew GM; GeneCentric Therapeutics, Inc., Durham, NC, USA., Shibata Y; GeneCentric Therapeutics, Inc., Durham, NC, USA., Eulitt P; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Uronis JM; GeneCentric Therapeutics, Inc., Durham, NC, USA., Zhou M; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Nielsen M; Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Smith AB; Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Woods M; Department of Urology, Loyola University, Chicago, IL, USA., Hayward MC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Salazar AH; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Wobker SE; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., McGinty K; Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Millburn MV; GeneCentric Therapeutics, Inc., Durham, NC, USA., Eisner JR; GeneCentric Therapeutics, Inc., Durham, NC, USA., Kim WY; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. wykim@med.unc.edu.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. wykim@med.unc.edu.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. wykim@med.unc.edu.
Publikováno v:
British journal of cancer [Br J Cancer] 2022 May; Vol. 126 (8), pp. 1237.
Autor:
Rose TL; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Weir WH; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Mayhew GM; GeneCentric Therapeutics, Inc., Durham, NC, USA., Shibata Y; GeneCentric Therapeutics, Inc., Durham, NC, USA., Eulitt P; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Uronis JM; GeneCentric Therapeutics, Inc., Durham, NC, USA., Zhou M; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Nielsen M; Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Smith AB; Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Woods M; Department of Urology, Loyola University, Chicago, IL, USA., Hayward MC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Salazar AH; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Wobker SE; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., McGinty K; Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Millburn MV; GeneCentric Therapeutics, Inc., Durham, NC, USA., Eisner JR; GeneCentric Therapeutics, Inc., Durham, NC, USA., Kim WY; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. wykim@med.unc.edu.; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. wykim@med.unc.edu.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. wykim@med.unc.edu.
Publikováno v:
British journal of cancer [Br J Cancer] 2021 Oct; Vol. 125 (9), pp. 1251-1260. Date of Electronic Publication: 2021 Jul 22.
Autor:
Faruki H; GeneCentric Diagnostics, Durham, North Carolina. Electronic address: Hawazin@genecentric.com., Mayhew GM; GeneCentric Diagnostics, Durham, North Carolina., Serody JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina., Hayes DN; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina., Perou CM; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; Department of Genetics, University of North Carolina, Chapel Hill, North Carolina., Lai-Goldman M; GeneCentric Diagnostics, Durham, North Carolina.
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2017 Jun; Vol. 12 (6), pp. 943-953. Date of Electronic Publication: 2017 Mar 21.
Autor:
Faruki H; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Mayhew GM; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Fan C; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Wilkerson MD; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Parker S; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Kam-Morgan L; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Eisenberg M; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Horten B; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Hayes DN; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Perou CM; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten)., Lai-Goldman M; From the Clinical Development Department, GeneCentric Diagnostics, Durham, North Carolina (Drs Faruki, Mayhew, and Lai-Goldman); the Lineberger Comprehensive Cancer Center (Mr Fan and Drs Hayes and Perou) and the Department of Genetics (Drs Wilkerson and Perou), University of North Carolina, Chapel Hill; and the Center for Molecular Biology and Pathology, Laboratory Corporation of America Holdings, Research Triangle Park, North Carolina (Mr Parker and Drs Kam-Morgan, Eisenberg, and Horten).
Publikováno v:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2016 Jun; Vol. 140 (6), pp. 536-42. Date of Electronic Publication: 2015 Oct 02.
Autor:
Wright FA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM, Corey M, Dorfman R, Goddard K, Green D, Kent JW Jr, Lange EM, Lee S, Li W, Luo J, Mayhew GM, Naughton KM, Pace RG, Paré P, Rommens JM, Sandford A, Stonebraker JR, Sun W, Taylor C, Vanscoy LL, Zou F, Blangero J, Zielenski J, O'Neal WK, Drumm ML, Durie PR, Knowles MR, Cutting GR
Publikováno v:
Nature genetics [Nat Genet] 2011 Jun; Vol. 43 (6), pp. 539-46. Date of Electronic Publication: 2011 May 22.
Autor:
Hancock DB; Center for Human Genetics, Duke University Medical Center, Durham, NC, USA. dana.hancock@duke.edu, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK
Publikováno v:
BMC neurology [BMC Neurol] 2008 Mar 28; Vol. 8, pp. 6. Date of Electronic Publication: 2008 Mar 28.